James D. Trenkle, Ph.D.
585 9th St, Oakland, CA 94607; (617) 642-4368
jim_trenkle@mba.berkeley.edu

Education

University of California Berkeley, Haas School of Business
Master of Business Administration, expected May 2016
- Emphasis in Finance, Entrepreneurship, and Strategy
- Haas Healthcare Conference Lead

Massachusetts Institute of Technology
Doctor of Philosophy in Organic Chemistry, May 2007
- Total synthesis of complex antifungal natural product (–)-gloeosporone, recognized as "Synthesis of the Month" on popular Totally Synthetic Blog, in laboratory of Professor Tim Jamison.
- President, Chemistry Graduate Student Council

University of Michigan Ann Arbor, School of Literature, Sciences, and Arts
Bachelors of Science in Honors Chemistry, May 2002
- Undergraduate thesis on allylborane chemistry with Professor Bill Roush
- Excellence in a wide range of activities and subjects – intramural tennis champion, social chair of Theta Xi, baritone in nationally recognized a capella choir Compulsive Lyres

Experience

2010 – **Gilead Sciences**, Project and Portfolio Management — Foster City, CA
Associate Director (2014 – present)
- Responsible for managing drug development activities for entire HCV portfolio (Sovaldi®, Harvoni®, velpatasvir, GS-9857), curing >100K patients and generating over $12B in revenue in 2014.
- As lead Project Manager for HCV Commercial Launch team, ensured alignment of a diverse cross-functional team of 20 Senior Managers and VPs
- Collaborated with SVP of Clinical Research to generate the strategic plan for Liver Fibrosis drug development. Influenced plan to expand number of indications, revenue potential, and earlier filing.
- Partnered with Medical Affairs, Commercial Planning, and Clinical Research to identify data gaps, which resulted in new studies used in supplemental regulatory filings.

Senior Manager (2010 – 2014)
- As lead Project Manager for Harvoni®, worked with cross-functional team to generate and execute the strategic development plan, resulting in launch of transformative cure for patients suffering from HCV.
- Managed HCV portfolio, generating strategy to prioritize resources towards more promising leads from earlier entities (eg ledipasvir and vedroprevir 2nd Gen HCV PI).
- Collaborated with Clinical Research and Commercial Strategy to generate and communicate target product profiles for HCV development candidates, resulting in an aligned strategy in HCV development.
- Displayed excellent verbal, written and interpersonal skills to lead and drive consensus among individuals from a variety of disciplines (e.g. commercial, clinical, regulatory, CMC, biology, virology, drug safety).

2007 – 2010 **Gilead Sciences,** Research — Foster City, CA
Research Scientist I (2007 – 2009)
Research Scientist II (2010)
- Insights into workings of chemical matter contributed to the discovery of several drug candidates, including ledipasvir (GS-5885). Elucidated the chemical mechanism of action for HCV drug candidate and defended data to SVP and VP leadership, advancing our understanding of an important drug development candidate.
- Championed the use of deuterium to increase metabolic stability on advanced drug candidates.

1999 – 2001 **Michigania,** University of Michigan Alumni Camp — Boyne City, MI
Director, Rifle Range
- Oversaw budget development and capital expenditures, managed a staff of four, and instituted an educational series to successfully run a safe and fun rifle range as an integral part of the Camp experience

Additional

- Led panels at sold-out Haas Healthcare Conference (November 2015) on Policy Impacts on Innovation and on Models for International Development
- Enjoy volleyball, hiking, urbanism, cooking, and travel

SELECT HONORS

2014-15	Selected to Gilead Mentorship Program, as mentor
2011-12	Selected to Gilead Mentorship Program (50 people company-wide selected), as mentee to the EVP
2010	Nominated to Faculty of 1000
2007	Thesis work featured in popular Chemistry Blog Totally Synthetic as "Synthesis of the Month"
2006	Gordon Research Conference Travel Grant
2005-06	President, Chemistry Graduate Student Council
2002	Merck Index Award to Outstanding Senior
1997	BSA Eagle Scout Awarded

SELECT PUBLICATIONS

Multiple Patents with Gilead Sciences, including composition of matter for GS-5885 (ledipasvir), composition of matter for tegobuvir-related program, additional HCV- and HIV-related (details on request).

A. Thompson, B. Kanwar, J. Trenkle "6 and 12 Weeks of Ledipasvir, Vedroprevir, and Peginterferon/Ribavirin for Patients with Genotype 1 HCV Infection and the IL28B CC Genotype" *Antiviral Therapy*, *accepted for publication.*

D. Wyles, B. Kanwar, J. Trenkle, P. Pang, M. Subramanian, J McHutchison, M. Sulkowski et al. "All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection" *Hepatology* **2014**, *60*, 56-64. *DOI: 10.1002/hep.27053*

GT Everson, J. D. Trenkle, B. Kanwar, M. Subramanian, J McHutchison et al. "Combination of the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, and pegylated interferon plus ribavirin in treatment experienced patients with genotype 1 hepatitis C infection" *48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013)* Amsterdam. April 24-28, 2013.

A Thompson, J. D. Trenkle, B. Kanwar, M. Subramanian, J McHutchison et al.
GS-5885 + GS-9451 + peginterferon and ribavirin (PR) for six or twelve weeks achieves high SVR12 rates in treatment-naive genotype 1 IL28B CC patients. 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam. April 24-28, 2013.

S Pol, J. D. Trenkle, B. Kanwar, M. Subramanian, J McHutchison et al.
Antiviral efficacy of the NS3 protease inhibitor, GS-9451, non-nucleoside NS5B inhibitor, tegobuvir, and pegylated interferon plus ribavirin in treatment-naive genotype 1 hepatitis C infected patients." 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam. April 24-28, 2013.

Hebner C. M.; Trenkle, J. D. et al "The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function" *PLoS One* **2012**, *7 (6)*, 1-9.

Trenkle, J. D.; Jamison, T. F. "Macrocyclization by Nickel-Catalyzed, Ester-Promoted, Epoxide-Alkyne Reductive Coupling: Total Synthesis of (-)-Gloeosporone" *Angew. Chem. Int. Ed.* **2009**, *48*, 5266-5368.
Featured "Synthesis of the Month" on Totally Synthetic blog: http://totallysynthetic.com/blog/?p=1838

Trenkle, J. D.; Jamison, T.F. "Macrocyclization by Nickel-Catalyzed, Ester-Promoted, Epoxide-Alkyne Reductive Coupling: Progress Towards the Total Synthesis of (-)-Gloeosporone." The 2006 Gordon Research Conference on Natural Products.

Heffron, T. P.; Trenkle, J. D.; Jamison, T. F. "Synthesis of Skipped Enynes via Phosphine-Promoted Coupling Reactions of Propargylcopper Reagents" *Tetrahedron* **2003**, *59*, *Symposium-In-Print, New Synthetic Methods VII*, 8913-8917.